

1 Nanopore Metagenomic Sequencing for Detection and Characterization of SARS-CoV-2 in Clinical
2 Samples

3
4 **Nick P.G. Gauthier¹, Cassidy Nelson², Michael B. Bonsall², Kerstin Locher^{3,4}, Marthe Charles^{3,4},**
5 **Clayton MacDonald^{3,4}, Mel Krajden^{4,5}, Samuel D. Chorlton^{4,6*}, Ameer R. Manges^{5,7*}**

6 ¹Department of Microbiology and Immunology, University of British Columbia, Vancouver, British
7 Columbia, Canada

8 ²Mathematical Ecology Research Group, Department of Zoology, University of Oxford, Oxford, United
9 Kingdom

10 ³Division of Medical Microbiology, Vancouver General Hospital, Vancouver, British Columbia, Canada

11 ⁴Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British
12 Columbia, Canada

13 ⁵British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada

14 ⁶BugSeq Bioinformatics Inc, Vancouver, British Columbia, Canada

15 ⁷School of Population and Public Health, University of British Columbia, Vancouver, British Columbia,
16 Canada

17

18 ***Denotes equal contribution**

19 **Corresponding authors:**

20 Samuel D. Chorlton, MD, sam@bugseq.com

21 Ameer R. Manges, MPH, PhD, amee.manges@ubc.ca

22

23 **Running Title:** Nanopore Metagenomic Sequencing of SARS-CoV-2

24

25 **Key words:** Nanopore, Metagenomic, SARS-CoV-2, Coronavirus, Molecular epidemiology, Diagnostic,
26 Sequence-independent single-primer amplification, NGS

27 **Abstract**

28

29 The COVID-19 pandemic has underscored the need for rapid novel diagnostic strategies to detect and
30 characterize pathogens from clinical specimens. The MinION sequencing device allows for rapid, cost-
31 effective, high-throughput sequencing; useful features for translation to clinical laboratory settings.

32 Metagenomic Next-Generation Sequencing (mNGS) approaches provide the opportunity to examine the
33 entire genomic material of a sample; allowing for detection of emerging and clinically relevant pathogens
34 that may be missed in targeted assays. Here we present a pilot study on the performance of Sequence-
35 Independent Single Primer Amplification (SISPA) to amplify RNA randomly for the detection and
36 characterization of SARS-CoV-2. We designed a classifier that corrects for barcode crosstalk between
37 specimens. Our assay yielded 100% specificity overall and 95.2% sensitivity for specimens with a RT-
38 qPCR cycle threshold value less than 30. We assembled 10 complete (>95% coverage at 20x depth), and
39 one near-complete (>80% coverage at 20x depth) genomes from 20 specimens that were classified as
40 positive by mNGS. We characterized these genomes through phylogenetic analysis and found that 10/11
41 specimens from British Columbia had a closest relative to another British Columbian specimen. Of five
42 samples that we had both assembled genomes, as well as Variant of Concern (VOC) PCR results, we
43 found 100% concordance between these results. Additionally, our assay was able to distinguish between
44 the Alpha and Gamma variants, which was not possible with our VOC PCR technique. This study
45 supports future work examining the broader feasibility of SISPA as a diagnostic strategy for the detection
46 and characterization of viral pathogens.

47

48 **Introduction**

49

50 The global COVID-19 pandemic and ensuing public health emergency has underscored the need for
51 rapid, comprehensive, and cost-effective viral testing strategies to respond effectively to outbreaks and
52 implement public health policy. COVID-19 disease is caused by severe acute respiratory syndrome

53 coronavirus 2 (SARS-CoV-2); a positive-sense RNA virus from the family *Coronaviridae* (1,2). The
54 current standard for the diagnosis of many viral infections, including SARS-CoV-2, is based on real-time
55 qualitative reverse transcription polymerase chain reaction (RT-PCR) assays (3). Due to its low cost,
56 reliability, and ability to diagnose infection known pathogens, RT-PCR has been at the forefront of viral
57 diagnostics before and during the COVID-19 pandemic (4). However, this method still requires many
58 hours of hands-on time by skilled laboratory technicians and is limited in that it only detects a
59 predetermined number of pathogens that its primers are designed to identify; unknown or unexpected
60 infectious agents will be missed (5). This is a strong rationale for exploring alternative diagnostic
61 strategies that can detect known and novel pathogens.

62
63 Metagenomic next generation sequencing (mNGS) allows all genetic material recovered directly from a
64 sample to be sequenced and analyzed in a culture-free manner. Sequence-independent single primer
65 amplification (SISPA) (6) is one such mNGS approach. SISPA enables non-selective reverse transcription
66 of all extracted RNA in a sample into cDNA and amplifies the reverse transcribed cDNA using random
67 nonamers tagged to a known primer sequence. This method has been successfully used to detect and
68 assemble genomes of avian RNA viruses (7), canine distemper virus (8), human enterovirus (9),
69 chikungunya virus, Ebola virus, hepatitis C virus (10), influenza virus (11), as well as SARS-CoV-2 for a
70 small number of samples (12,13). Therefore, there is a strong justification for using this approach to
71 enable detection of pathogenic agents in diagnostic laboratories.

72
73 SISPA and mNGS have several clear advantages over targeted molecular approaches. mNGS enables
74 detection of multiple pathogens and co-infection in a clinical sample, as well as potentially providing
75 information on antimicrobial resistance, virulence, and microbiota-associated dysbiosis at a particular
76 body site (14,15). Despite the potential advantages of this approach for clinical applications, mNGS
77 techniques have not yet been widely adopted due to their high-cost, time-intensive sample preparation,
78 limited access to sequencing infrastructure and lack of robust, easy-to-use and interpret bioinformatics

79 systems (14). Furthermore, the FDA has provided no specific requirements for validation of mNGS-based
80 diagnostic assays; which has made validation and translation of mNGS tools for detection of
81 microorganisms challenging for routine clinical microbiology laboratories (15).

82
83 The Oxford Nanopore Technologies' (ONT) MinION sequencing platform provides a method for high-
84 throughput, and cost-effective long-read sequencing in a device that fits in the palm of a hand.
85 Sequencing on the MinION device is also less time-intensive than the Illumina sequencing platform
86 (14,16). The portability and cost-effectiveness of MinION sequencing makes Nanopore mNGS uniquely
87 tailored for clinical applications. Despite these advances in long-read clinical sequencing applications, the
88 field of nanopore clinical metagenomics has been largely unexplored. To date, there are only a few
89 studies that examine the use of nanopore-based metagenomics for clinical applications (10,11,17,18).

90
91 Bioinformatic analysis is also a considerable barrier to adoption of mNGS for clinical diagnostics. The
92 majority of available tools require command line knowledge, significant computing infrastructure, and
93 experience translating bioinformatic results into actionable results (15,19). As well, traditional short read
94 analysis services, such as One Codex and IDseq, were not designed or evaluated with third-generation
95 data (20,21). Several tools have been developed recently to facilitate analysis specifically of nanopore
96 mNGS data, including BugSeq and EPI2ME (22, <https://epi2me.nanoporetech.com>). BugSeq is a
97 bioinformatics solution designed for clinical microbiology labs, enabling the end-to-end analysis of
98 nanopore sequencing data with a graphical user interface and cloud-based data processing. Its analytical
99 method has been shown to have superior sensitivity and specificity compared to EPI2ME (22), and will
100 be the primary analysis pipeline used in this study.

101
102 In this pilot study, we examine the feasibility and performance of a SISPA-based Nanopore mNGS assay
103 to detect and characterize SARS-CoV-2 from two distinct study populations using the MinION
104 sequencing device.

105

106 **Materials & Methods**

107 *Study population and specimen collection:*

108 Clinical specimens were collected from two different populations. First, oropharyngeal swabs were
109 collected in 2 mL of a guanidinium-based inactivation agent (Prestige Diagnostics) as part of a study
110 conducted to estimate SARS-CoV-2 infection prevalence in a UK community from April to June 2020.
111 Swab samples from 2714 individuals from around the greater Oxford area were collected to compare
112 PCR, serology, and Nanopore sequencing for SARS-CoV-2 infected versus uninfected subjects. A set of
113 eight SARS-CoV-2 PCR positives or indeterminate samples from this population were included in the
114 current study. Second, nasopharyngeal swab specimens collected in 3 mL viral transport medium (Yocon
115 Bio-technology Co. Ltd) were obtained from routine SARS-CoV-2 community testing at Vancouver
116 General Hospital (VGH) or the BC Centre for Disease Control (BCCDC) (Vancouver, British Columbia,
117 Canada) (n = 35). RT-PCR testing for COVID-19 was performed for all samples at either the BCCDC
118 Public Health Laboratory or the medical microbiology laboratory at VGH using either the Roche MagNA
119 Pure extraction system (Roche Diagnostics, Laval, Canada) in combination with detection of E-gene and
120 RdRp gene targets, or the Panther Fusion SARS-CoV-2 assay (Hologic Inc., San Diego, CA) detecting
121 two targets in ORF1ab. Primers for the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) were
122 developed in-house by the BCCDC Public health laboratory and primers for the E gene were based on the
123 World Health Organization RT-qPCR protocol (3). The human RNaseP gene was used as an internal
124 control as suggested by the World Health Organization
125 ([https://www.who.int/csr/resources/publications/swineflu/CDCRealtimeRTPCR_SwineH1Assay-
126 2009_20090430.pdf?ua=1](https://www.who.int/csr/resources/publications/swineflu/CDCRealtimeRTPCR_SwineH1Assay-2009_20090430.pdf?ua=1)). A table containing primers and probes used for these assays can be found in
127 Supplementary Table 1. Additionally, PCR screening for potential variants of concern (VOCs) (Ex.
128 Alpha, Beta, Gamma, Delta variants) was performed on 11 of the positive swabs obtained from VGH that
129 were collected during May 2021. Primers and probes were designed to target the N501Y and E484K
130 mutations (Supplementary Table 2). Swabs were stored at either -80°C for the oropharyngeal swabs or -

131 20°C for the nasopharyngeal swabs. Specimens were chosen to obtain test performance metrics for
132 Nanopore mNGS across a range of C_t values (Supplementary Figure 1).

133

134 *RNA Extractions:*

135 Prior to extraction, samples were vortexed and 200 uL of each sample was centrifuged at 16,000g for 3
136 minutes to pellet host cells. 140 uL of supernatant was aspirated and viral RNA was extracted from the
137 supernatant using the QIAmp Viral RNA kit (Qiagen) as previously described (11), and eluted in 30 uL
138 nuclease-free water. Samples were treated with TURBO DNase (Thermo Fisher Scientific) and incubated
139 at 37°C for 30 minutes, followed by concentration and clean-up with the RNA Clean & Concentrator-5 kit
140 (Zymo Research); finally, eluting in 8 uL nuclease-free water.

141

142 *SISPA Amplification:*

143 SISPA amplification was performed as described previously (9-13). Briefly, concentrated RNA was
144 incubated with primer A (100pmol/uL; 5' - GTTTCCTACTGGAGGATA(N₉) - 3') and then reverse
145 transcribed using SuperScript IV Reverse Transcriptase (Thermo Fisher Scientific). Second strand
146 synthesis was performed using Sequenase Version 2.0 (Thermo Fisher Scientific), following which,
147 RNase H was performed to digest any remaining RNA. Random amplification was performed on each
148 using AccuTaq LA DNA polymerase (Thermo Fisher Scientific) and SISPA primer B (5' -
149 GTTTCCTACTGGAGGATA - 3'). This reaction underwent PCR using the following conditions: initial
150 denaturation for 30 seconds at 98°C, followed by 30 cycles of 94°C for 15 seconds, 50°C for 20 seconds,
151 and 68°C for 2 minutes. A final elongation step of 68°C for 10 minutes was added, prior to a final hold at
152 4°C. Amplified cDNA was purified using a 1:1 ratio of PCR Clean DX beads (Aline Biosciences) and
153 eluted in 50 uL nuclease-free water. Amplified cDNA was quantified using a Qubit 4 Fluorometer
154 (Thermo Fisher Scientific) and fragment lengths were assessed using the TapeStation 2200 automated
155 electrophoresis platform (Agilent).

156

157 *Library Preparation and MinION Sequencing:*

158 Library preparation was performed using ONT's ligation sequencing kit (SQK-LSK109 or SQK-
159 LSK110). Multiplexing was performed using the native barcoding expansion 96 kit (EXP-NBD196).
160 Library preparation was performed according to the manufacturer's instructions, with several key
161 modifications. DNA repair and end-prep was performed with 1000 fmol of input cDNA and the
162 incubation times were increased to 30 minutes at 20°C, followed by 30 minutes at 65°C. For the
163 barcoding reaction 200 fmol of input cDNA was incubated with the native barcodes and Blunt/TA Ligase
164 Master Mix (New England Biolabs) for 20 minutes at room temperature (15-25°C), followed by 10
165 minutes at 65°C to improve barcode ligation efficiency with smaller fragments. Up to four clinical
166 samples (90 fmol/sample) were multiplexed on each minION flowcell, with the addition of a blank viral
167 transport medium negative control sample to each pooled library. Samples were sequenced on FLO-
168 MIN106 flowcells on MinION MK1b sequencing devices for 72 hours using MinKNOW (Version 4.2.8,
169 Oxford Nanopore Technologies) with live basecalling disabled.

170

171 *Sequence Data Analysis:*

172 Raw fast5 files were basecalled using Guppy (Version 5.0.7, Oxford Nanopore Technologies) using the --
173 *device cuda:0* flag to enable GPU basecalling. Output fastq files were uploaded to BugSeq (version 1.1,
174 database version: RefSeq on Jan 28, 2021) for metagenomic classification (22), and results classification
175 results were visualized in Recentrifuge (23). A representative html file containing an example
176 visualization output can be found in the supplemental material (Supplementary Data). In brief, reads were
177 demultiplexed with qcat using default run parameters (enforcing barcodes on both ends, which we have
178 defined as stringent demultiplexing), followed by quality control with prinseq-lite. Reads shorter than
179 100bp or those deemed low quality (DUST score less than 7) were discarded. Reads were then classified
180 against all of the microbial genomes in RefSeq, as well as the human genome and a library of common
181 contaminants (see 22 for details). Reads classified as SARS-CoV-2 were extracted and used to build a
182 consensus sequence with Medaka. Bases with less than 20X coverage were masked in accordance with

183 public SARS-CoV-2 sequencing guidelines (<https://www.aphl.org/programs/preparedness/Crisis->
184 [Management/Documents/APHL-SARS-CoV-2-Sequencing.pdf](https://www.aphl.org/programs/preparedness/Crisis-Management/Documents/APHL-SARS-CoV-2-Sequencing.pdf)). SARS-CoV-2 lineages were assessed
185 using Pangolin (Version 3.1.5, github.com/cov-lineages/pangolin), and phylogenetic analysis was
186 performed with UShER (24) (Database: GISAID, GenBank, COG-UK and CNCB [2021-07-11]).
187 Phylogenetic trees were constructed using augur (25), rooted at the SARS-CoV-2 reference sequence, and
188 visualized in iTOL (26). Antimicrobial resistance genes were detected by aligning reads against the
189 Resfinder database (27) with minimap2, disabling secondary alignments. Analysis from BugSeq outputs
190 and visualizations were performed in RStudio (R version 4.1.0) and Python, with all code available at
191 <https://gitlab.com/bugseq/sars-cov-2-nanopore-mngs-performance> (28).

192

193 *Ethics Approval:*

194 This study obtained research ethics board approval from the University of British Columbia (H20-02152).
195 Approval for collection of participant data was obtained by the Central University Research Ethics
196 Committee at the University of Oxford (R69035). Specimens collected as part of routine testing at VGH
197 and the BCCDC were de-identified and only contained a sample ID number, collection date, C_t , and VOC
198 screening result.

199

200 *Data Availability:*

201 Raw FASTQ data has been uploaded to NCBI Bioproject Accession PRJNA752146. Raw reads were
202 mapped against the human reference genome and transcriptome (Ensembl hg38) using minimap2 (2.20)
203 (29) and any human reads were removed.

204

205 **Results:**

206 *Sequence data & Sample Descriptions:*

207 Amplified cDNA from a total of 43 patient swabs were sequenced on MinION sequencing devices. Of
208 these samples, 38 were either positive or had indeterminate results based on SARS-CoV-2 RT-PCR and 5

209 samples had negative RT-PCR results. The 38 positive and indeterminate samples had a mean C_t value of
210 27.6 and ranged from 14.7-38.7 (Supplementary Figure 1). Sample collection dates, sample type, total
211 read counts, as well as dual barcode reads, percent human reads, and SARS-CoV-2 reads per million
212 reads sequenced (RPM) are present in Table 1. On average, negative controls exhibited a 29.7-fold
213 decrease in dual barcode reads compared to the average number of dual barcode specimen reads (Mean
214 dual barcode reads = 20,013, Q1: 158.5, Q3: 17556). SARS-CoV-2 was detected in similar abundance
215 across our six positive control samples (Mean RPM Dual Barcode: $103,521 \pm 21,070$)

216

217 *Sensitivity, Specificity, & Limit of Detection:*

218 We evaluated the test performance of our mNGS assay for detecting SARS-CoV-2. A sample was
219 considered positive if one or more reads were assigned to SARS-CoV-2. Across all clinical samples, we
220 detect SARS-CoV-2 with 78.4% (95%CI 62.8%-88.6%) sensitivity and 100% specificity (95%CI 56.6%-
221 100%) (Table 2). Previous literature has demonstrated decreased sensitivity of mNGS assays above C_t 30
222 for other viruses (11,30). To assess the dependence of the mNGS assay on C_t value, we performed a
223 subgroup analysis on samples above and below SARS-CoV-2 C_t 30. For samples with SARS-CoV-2 C_t <
224 30, sensitivity was 100% (95%CI 84.5%-100%), while for samples with SARS-CoV-2 C_t greater than 30,
225 sensitivity was 50% (95%CI 27.8%-72.0%).

226

227 We note that two of 11 negative control samples had a single read assigned to SARS-CoV-2. We
228 investigated these reads (further denoted as read one and two) to identify reasons for false positivity. Both
229 reads had the expected barcode on both ends of the read as identified by BLAST. The first read exhibited
230 100% identity over the 24 nucleotide barcode on both ends, and the second read had 100% and 83%
231 identity over the 24 nucleotide barcode on both ends. We next search these reads against the NCBI
232 nucleotide database using megaBLAST to assess whether a BugSeq classification error occurred.
233 However, both reads had top hits that exclusively matched SARS-CoV-2 with greater than 95% identity
234 over more than 90% of their total length (923 and 1752 bases, respectively). SARS-CoV-2 was detected,

235 despite strict dual barcode demultiplexing and removal reads with improper barcode insertions. Previous
236 studies have identified barcode crosstalk, ranging from 0.2% to 0.3% of total classified reads, on
237 Nanopore MinION flowcell results (31,32). When we examined the total SARS-CoV-2 read counts for a
238 given flowcell on flowcells with false positive negative controls, we saw that one of those flowcells has
239 the highest total SARS-CoV-2 read count of all flowcells in this study, therefore, we would expect higher
240 levels of barcode crosstalk for that flowcell (Supplementary Figure 2).

241
242 We adjusted for barcode crosstalk by controlling for the total number of dual-barcoded SARS-CoV-2
243 reads on each flowcell. If we assume 0.2% of reads have incorrect barcodes ligated on both ends, and that
244 these misclassified reads are evenly distributed across all barcodes on the flowcell, we can subtract the
245 estimated number of misclassified reads from each sample. This correction yielded an acceptable
246 threshold for classifying specimens as positive or negative. After adjusting for barcode crosstalk in this
247 manner, we find that seven samples and two negative controls with SARS-CoV-2 reads detected would be
248 re-classified as negative, and all negative controls are therefore classified correctly. The overall sensitivity
249 and specificity on clinical samples after adjusting for barcode crosstalk are estimated to be 59.5% (95% CI
250 43.5%-73.7%) and 100% (56.6%-100%), respectively. Grouping by C_t value, the sensitivity estimates are
251 95.2% (95% CI 77.3%-99.2%) and 12.5% (95% CI 3.5%-36.0%) for samples below and above C_t 30,
252 respectively (Table 3).

253
254 *RT-qPCR/SISPA Correlation, Genome Coverage, & SARS-CoV-2 Phylogeny:*

255 We assessed the relationship between SARS-CoV-2 RT-PCR C_t value and SARS-CoV-2 RPM for dual
256 barcode reads, using stringent demultiplexing analysis parameters. SARS-CoV-2 log-RPM showed a
257 strong linear association with RT-qPCR C_t value ($R^2 = 0.71$), with lower C_t values having a higher RPM
258 on average (Figure 1). This relationship did not differ by RT-qPCR gene target (E-gene, ORF1ab, or
259 RdRp) (Supplementary Figure 3). SARS-CoV-2 genome coverage depth showed a similar relationship,
260 with decreasing coverage depth across the entire genome being associated with increasing C_t value

261 (Figure 2, Table 4). We produced logistic regression models to assess the probability of attaining greater
262 than 95% genome coverage at 1X, 20X, or 50X depth of coverage. We found that for every one unit
263 increase in C_t value, the odds of recovering a 95% complete genome were 0.765 (95% CI: 0.519, 0.961),
264 0.263 (95% CI: 0.023, 0.666), or 0.263 (95% CI 0.023, 0.666) on average for coverage depths of 1X,
265 20X, or 50X, respectively (Figure 3). Interestingly, we did not see any difference in the likelihood of
266 obtaining 95% coverage for 20X or 50X, despite slight differences in coverage depth for both of these
267 thresholds (Table 4; Figure 3).

268
269 SARS-CoV-2 metagenomic reads were used to reconstruct viral genomes. We produced ten complete
270 (greater than 95% unambiguous bases) and one near-complete consensus genome sequence (greater than
271 80% unambiguous bases) from our 20 SISPA-positive clinical specimens, masking any bases with less
272 than 20X coverage. Two partial viral genomes were constructed with 20-25% unambiguous bases.
273 Pangolin lineage assignment was successful to all complete or near complete genomes; of these five
274 underwent SARS-CoV-2 VOC PCR testing. All five whole or partial viral genomes were classified as
275 SARS-CoV-2 lineages concordant with PCR results (Table 5). We also detected an additional VOC in a
276 sample that did not undergo VOC PCR testing. We also assessed our complete or near-complete
277 genomes in the context of global SARS-CoV-2 transmission by placing them in a phylogenetic tree
278 containing over two million publicly available SARS-CoV-2 genomes. The ten complete genomes could
279 be placed in the global phylogeny with high confidence (only one maximally parsimonious placement),
280 and the near-complete genome could be placed with lower confidence (nine maximally parsimonious
281 placements). For ten of 11 genomes derived from metagenomic data, the nearest neighbor in this tree was
282 a genome derived from the same province of sample collection, British Columbia. Additionally, for 9/11
283 study genomes, 80% or more of the nearest 50 genomes were derived from British Columbia; for the
284 remaining two study genomes, 90% or more of the nearest 50 genomes were derived from Canada (Figure
285 4; Supplementary Figure 4). The UK samples did not yield well covered genomes. Subtrees with nearest
286 neighbors for all study samples are available in the supplementary material (Supplementary Figure 4).

287

288 *Universal Microbial Detection & Antimicrobial Resistance:*

289 We searched the BugSeq metagenomic output of our clinical specimens for alternative respiratory viruses
290 or viral or bacterial co-infections. We did not identify any other pathogenic viruses or atypical bacteria
291 such as *Chlamydia pneumoniae* or *Mycoplasma pneumoniae*. We did identify several members of the
292 normal nasopharyngeal microbiota, which when found in the lower respiratory tract, may cause disease;
293 these included two samples with *Moraxella catarrhalis*, seven samples with *Haemophilus influenzae* or
294 *Haemophilus parainfluenzae*, three samples with *Neisseria meningitidis*, three samples with
295 *Staphylococcus aureus*, two samples with *Streptococcus pneumoniae* and two samples with *Klebsiella*
296 *pneumoniae* (Supplementary Table 3). These results are consistent with other metagenomic sequencing
297 results from the nasopharynx (30). We searched our data for genes conferring antimicrobial resistance,
298 and identified 10 genes across 6 samples. We found two beta-lactamases in our dataset: *blaTEM-234*, a
299 class A beta-lactamase which has undetermined spectrum and derived from *Escherichia coli* in sample
300 P22, as well as *blaOXA-85*, which confers resistance to amoxicillin and amoxicillin-clavulanate, that
301 derived from *Fusobacterium psuedoperiodonticum* (P9).

302

303 **Discussion:**

304 Here, we present a robust analysis detailing the performance of SISPA coupled with Nanopore mNGS to
305 detect and characterize SARS-CoV-2 from clinical samples. Clinical specimens exhibiting a $C_t < 30$
306 performed well. However, test performance declined in specimens exhibiting a $C_t \geq 30$ from 96.3%
307 sensitivity for samples below C_t 30 to 12.5% for samples above this cycle threshold. We found an
308 exponentially declining relationship between RPM and C_t value, such that the instantaneous change in
309 read performance was fixed as illustrated in the linear relationship between $\text{Log}(\text{RPM})$ and C_t value
310 (Figure 1). This finding is consistent with other reports on the use of SISPA and Nanopore mNGS for
311 respiratory infections (11,33). However, our results are not consistent with SISPA and mNGS results
312 from blood and serum viral diagnostics, where C_t value did not drastically impact genome coverage (34).

313 These inconsistent results may have been influenced by sample type, sample preparation and the relative
314 abundance of host nucleic acid in different sample types.

315
316 Despite limitations in SISPA and Nanopore metagenomic sequencing sensitivity, this approach remains a
317 valuable technique for the detection of pathogens that are novel, unexpected or uncharacterized, and
318 therefore unsuitable for targeted approaches such as RT-qPCR or emerging CRISPR-Cas-based
319 diagnostics, which focus only on known pathogens (35). Unlike these existing diagnostic methods,
320 Nanopore mNGS can theoretically detect any pathogen and co-infections, characterize changes in the site-
321 specific microbiota, and capture the carriage of critical virulence or antibiotic-resistant organisms or
322 genes, all of which can impact patient outcomes. Our approach identified several organisms in the
323 nasopharyngeal microbiota that may cause disease in the lower respiratory tract, consistent with
324 sequencing results from a recent study (30). We also did not detect any viral or atypical bacterial co-
325 infections (Supplementary Table 3), concordant with previous reports of a low prevalence of respiratory
326 co-infection in COVID-19 positive samples (36-38). In support of this finding, our study regions saw a
327 dramatic reduction in incidence of other respiratory viruses (eg., influenza and RSV) and bacterial
328 pathogens over our collection period, thought to be secondary to public health interventions.

329
330 We additionally assessed the ability of SISPA-based mNGS to classify and assemble complete or partial
331 SARS-CoV-2 genomes from RT-qPCR positive specimens. This method can perform dual diagnostic and
332 molecular epidemiology functions. Reliably, we were able to assemble near-complete genomes
333 (minimum 20X coverage) up to C_t 25, underscoring the ability of this approach not only to detect
334 emerging pathogens, but also to characterize them without *a priori* knowledge of a pathogen's genome
335 sequence. This ability contrasts to amplicon-based sequencing methods, which require the viral sequence
336 to develop primers (39). We performed lineage typing on metagenomic-derived SARS-CoV-2 genomes
337 and found perfect concordance with VOC PCR on a small subset of our samples. Moreover, with the
338 complete and partial genomes we were able to distinguish the P.1 variant from the B.1.351 variant, which

339 the PCR assay was unable to do, as both variants contain the E484K and N501Y mutations in their spike
340 genes targeted by the PCR assay. Our reconstructed viral genomes were further validated through
341 phylogenetic analyses, where 10/11 samples that were of British Columbian origin were most closely
342 related to another British Columbia genome sequence. This highlights the potential of mNGS sequencing
343 to be an all-in-one assay which detects and characterizes pathogens of interest in near real-time, providing
344 critical information for clinical care, infection prevention and control and public health interventions .

345
346 This study examined the methodological feasibility and validity of Nanopore mNGS. We observed false
347 positive SARS-CoV-2 reads in our negative control samples despite meticulous laboratory preparation,
348 including performing nucleic acid extractions in a biological safety cabinet, using freshly aliquoted
349 reagents, decontamination of all surfaces with ethanol and RNaseZap (Thermo Fisher Scientific), and
350 performing pre-amplification steps in a dedicated PCR area. After investigating these reads, we attribute
351 them to barcode crosstalk, in accordance with previous studies (30,31). While BugSeq implements
352 methods to minimize barcode crosstalk from Nanopore sequencing, including requiring barcodes to be
353 present at both ends of each read and removal of reads with barcodes integrated elsewhere, we developed
354 a method to adjust the total read counts on a flowcell for barcode crosstalk. These enhancements
355 improved assay specificity; however, sensitivity is negatively impacted by this read count adjustment.
356 Interestingly, using the estimated 0.2% expected crosstalk between barcodes based on existing reports in
357 the literature, we find far fewer false positive reads in our negative controls than would be expected (1
358 read found in each versus 3 and 107 reads expected). We do note that native barcoding on the Nanopore
359 platform is not fully optimized, leading to a significant portion of reads with only a single barcode in our
360 sequencing datasets. This results in a decreased sensitivity, when requiring that barcodes be present on
361 both read ends. Future advances in sequencing chemistry may reduce the prevalence of barcode crosstalk
362 while preserving assay sensitivity.

363

364 In addition to employing automated demultiplexing and minimizing barcode crosstalk for Nanopore
365 mNGS, we validated the BugSeq as a potentially powerful clinical bioinformatics platform and workflow,
366 including quality control, data visualization, taxonomic classification, consensus sequence generation,
367 data aggregation, and results reporting. Although a lack of straight-forward and user-friendly
368 bioinformatics pipelines has long been a deterrent for clinical laboratories implementing NGS and mNGS
369 methods, our use of BugSeq as a rapid and robust bioinformatics tool has demonstrated the utility of user-
370 friendly platforms for clinical diagnostics and public health service. Indeed, other groups adopting
371 MinION sequencers in clinical microbiology laboratories have reached similar conclusions (40,41).

372
373 Our pilot study has several limitations. Despite the MinION sequencing device providing high-throughput
374 sequencing data in real-time, this protocol is still significantly more time intensive than RT-PCR as a
375 diagnostic method, requiring a minimum of 12 hours from sample collection to prepared library, and
376 another 72 hours of sequencing to reach maximal pathogen detection sensitivity (although results could be
377 available in as little as 1-2 hours for high viral load samples). The use of liquid handling robots for
378 automated sample extraction, nucleic acid amplification, and library preparation may aid in
379 standardization. Additionally, examining the feasibility of a less time intensive library preparation
380 protocol such as the Rapid Barcoding Kit (Oxford Nanopore Technologies) for this approach will aid in
381 the optimization and translation of Nanopore mNGS for routine clinical use. The SISPA approach is also
382 limited in that it performs random amplification of both host and microbial nucleic acids. The high
383 percentage of host RNA in nasopharyngeal/oropharyngeal swabs limits our ability to rapidly detect
384 viruses with comparable sensitivity to PCR, requiring deeper sequencing than what is currently feasible
385 on a MinION. Therefore, this sequencing strategy may not be optimal for samples expected to have very
386 few viral or bacterial nucleic acids where sensitivity is paramount. We note that while assay sensitivity
387 has played an important role in public discourse surrounding SARS-CoV-2 testing, there is some data to
388 suggest that lower viral loads cannot be cultured and are less likely to be transmissible
389 (<https://www.idsociety.org/globalassets/idsa/public-health/covid-19/idsa-amp-statement.pdf>). This issue

390 is further complicated by the difficulty of employing host nucleic acid removal techniques on low-
391 biomass samples. Interestingly, the detection of host nucleic acids via mNGS may be useful, as samples
392 with lower host nucleic acid content have been shown to be associated with higher rates of false-negative
393 COVID-19 RT-PCR tests, presumably due to sample quality (42). Regardless, methods to enrich for
394 pathogen sequences or deplete host DNA to increase sensitivity have been examined (43-45), and may
395 prove useful for future clinical metagenomics studies.

396

397 Our pilot study represents the first analysis of performance and feasibility of SISPA-based Nanopore
398 mNGS for the detection and characterization of SARS-CoV-2. We were able to successfully detect
399 SARS-CoV-2 with 100% specificity and near perfect sensitivity for samples below C_t 30 when adjusting
400 for barcode crossover. We were also able to assemble SARS-CoV-2 genomes and characterize viral
401 lineages reliably in 10/13 of samples below C_t 25. This assay has the ability not only to detect known
402 pathogens and co-infections, but can also detect emerging pathogens, assess microbiota states, and
403 capture resistance and virulence genes. This approach holds promise as a tool for clinical diagnostics and
404 public health surveillance.

405

406

407

408

409

410

411

412

413

414

415

416 **References:**

- 417 1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Yuan ML,
418 Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ. 2020. A new
419 coronavirus associated with human respiratory disease in China. *Nature* 579:265–269.
- 420 2. Tavares R de CA, Mahadeshwar G, Pyle AM. 2020. The global and local distribution of RNA
421 structure throughout the SARS-CoV-2 genome. *J Virol* <https://doi.org/10.1101/2020.07.06.190660>.
- 422 3. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S,
423 Schneider J, Luisa Schmidt M, GJC Mulders D, Haagmans BL, van der Veer B, van den Brink S,
424 Wijsman L, Goderski G, Romette J-L, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C,
425 Koopmans MP, Drosten C, Victor CM, Olfert L, Marco K, Richard M, Adam M, Daniel CK, Tobias
426 B, Sebastian B, Julia S, Marie Luisa S, Daphne GJC M, Bart HL, der Veer Bas V, den Brink Sharon
427 V, Lisa W, Gabriel G, Jean-Louis R, Joanna E, Maria Z, Malik P, Herman G, Chantal R. 2020.
428 Detection of 2019 -nCoV by RT-PCR. *Euro Surveill* 25:1–8.
- 429 4. Li X, Geng M, Peng Y, Meng L, Lu S. 2020. Molecular immune pathogenesis and diagnosis of
430 COVID-19. *J Pharm Anal* 10:102–108.
- 431 5. Esbin MN, Whitney ON, Chong S, Maurer A, Darzacq X, Tjian R. 2020. Overcoming the bottleneck
432 to widespread testing: A rapid review of nucleic acid testing approaches for COVID-19 detection.
433 *Cold Spring Harb Lab Press* 26:771–783.
- 434 6. Reyes GR, Kim JP. Sequence-independent, single-primer amplification (SISPA) of complex DNA
435 populations. *Mol Cell probes* 5:473–481.
- 436 7. Chrzastek K, Lee D hun, Smith D, Sharma P, Suarez DL, Pantin-Jackwood M, Kapczynski DR.
437 2017. Use of Sequence-Independent, Single-Primer-Amplification (SISPA) for rapid detection,
438 identification, and characterization of avian RNA viruses. *Virology* 509:159–166.

- 439 8. Peserico A, Marcacci M, Malatesta D, Di Domenico M, Pratelli A, Mangone I, D’Alterio N,
440 Pizzurro F, Cirone F, Zaccaria G, Cammà C, Lorusso A. 2019. Diagnosis and characterization of
441 canine distemper virus through sequencing by MinION nanopore technology. *Sci Rep* 9:1–9.
- 442 9. Wollants E, Maes P, Merino M, Bloemen M, Van Ranst M, Vanmechelen B. 2020. First genomic
443 characterization of a Belgian Enterovirus C104 using sequence-independent Nanopore sequencing.
444 *Infect Genet Evol* 81:104267.
- 445 10. Greninger AL, Naccache SN, Federman S, Yu G, Mbala P, Bres V, Stryke D, Bouquet J, Somasekar
446 S, Linnen JM, Dodd R, Mulembakani P, Schneider BS, Muyembe-Tamfum JJ, Stramer SL, Chiu
447 CY. 2015. Rapid metagenomic identification of viral pathogens in clinical samples by real-time
448 nanopore sequencing analysis. *Genome Med* 7:1–13.
- 449 11. Lewandowski K, Xu Y, Pullan ST, Lumley SF, Foster D, Sanderson N, Vaughan A, Morgan M,
450 Bright N, Kavanagh J, Vipond R, Carroll M, Marriott AC, Gooch KE, Andersson M, Jeffery K, Peto
451 TEA, Crook DW, Sarah Walker A, Matthews PC. 2020. Metagenomic nanopore sequencing of
452 influenza virus direct from clinical respiratory samples. *J Clin Microbiol* 58:1–15.
- 453 12. Moreno GK, Braun KM, Halfmann PJ, Prall TM, Riemersma KK, Haj AK, Lalli J, Florek KR,
454 Kawaoka Y, Friedrich TC, O’Connor DH. 2020. Limited SARS-CoV-2 diversity within hosts and
455 following passage in cell culture. *bioRxiv* 2020.04.20.051011.
- 456 13. Moore SC, Penrice-randal R, Alruwaili M, Dong X, Pullan ST, Carter DP, Bewley K, Zhao Q, Sun
457 Y, Hartley C, Zhou E, Solomon T, Beadsworth MJB, Bogaert D, Crook DW, Matthews DA,
458 Andrew D, Mahmood Z, Aljabr W, Druce J, Vipond RT. 2020. Amplicon based MinION
459 sequencing of SARS-CoV-2 and metagenomic characterisation of nasopharyngeal swabs from
460 patients with COVID-19. *medRxiv* 2020.03.05.20032011.
- 461 14. Petersen LM, Martin IW, Moschetti WE, Kershaw CM, Tsongalis GJ. 2020. Third-Generation
462 Sequencing in the Clinical Laboratory : Exploring the Advantages and Challenges of Nanopore
463 Sequencing. *J Clin Microbiol* 58:1–10.

- 464 15. Chiu CY, Miller SA. 2019. Clinical metagenomics. *Nat Rev Genet* 20:341–355.
- 465 16. Forbes JD, Knox NC, Peterson C, Reimer AR. 2018. Highlighting Clinical Metagenomics for
466 Enhanced Diagnostic Decision-making : A Step Towards Wider Implementation. *Comput Struct*
467 *Biotechnol J* 16:108–120.
- 468 17. Charalampous T, Kay GL, Richardson H, Aydin A, Baldan R, Jeanes C, Rae D, Grundy S, Turner
469 DJ, Wain J, Leggett RM, Livermore DM, O’Grady J. 2019. Nanopore metagenomics enables rapid
470 clinical diagnosis of bacterial lower respiratory infection. *Nat Biotechnol* 37:783–792.
- 471 18. Schmidt K, Mwaigwisya S, Crossman LC, Doumith M, Munroe D, Pires C, M. Khan A, Woodford
472 N, Saunders NJ, Wain J, O’Grady J, Livermore DM. 2017. Identification of bacterial pathogens and
473 antimicrobial resistance directly from clinical urines by nanopore-based metagenomic sequencing. *J*
474 *Antimicrob Chemother* 72:104–114.
- 475 19. Chiang AD, Dekker JP. 2020. From the pipeline to the bedside: Advances and challenges in clinical
476 metagenomics. *J Infect Dis* 221:S331–S340.
- 477 20. Minot S, Krumm N, Greenfield N. 2015. One Codex: A Sensitive and Accurate Data Platform for
478 Genomic Microbial Identification. *bioRxiv* 027607.
- 479 21. Kalantar KL, Carvalho T, De Bourcy CFA, Dimitrov B, Dingle G, Egger R, Han J, Holmes OB,
480 Juan YF, King R, Kislyuk A, Lin MF, Mariano M, Morse T, Reynoso L V., Cruz DR, Sheu J, Tang
481 J, Wang J, Zhang MA, Zhong E, Ahyong V, Lay S, Chea S, Bohl JA, Manning JE, Tato CM, DeRisi
482 JL. 2021. IDseq-An open source cloud-based pipeline and analysis service for metagenomic
483 pathogen detection and monitoring. *Gigascience* 9:1–14.
- 484 22. Fan J, Huang S, Chorlton SD. 2021. BugSeq: a highly accurate cloud platform for long-read
485 metagenomic analyses. *BMC Bioinformatics* 22:1–12.
- 486 23. Martí JM. 2019. Recentrifuge: Robust comparative analysis and contamination removal for
487 metagenomics. *PLoS Comput Biol* 15:1–24.

- 488 24. Turakhia Y, Thornlow B, Hinrichs AS, De Maio N, Gozashti L, Lanfear R, Haussler D, Corbett-
489 Detig R. 2021. Ultrafast Sample placement on Existing tRees (UShER) enables real-time
490 phylogenetics for the SARS-CoV-2 pandemic. *Nat Genet* 53:809–816.
- 491 25. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P, Bedford T, Neher
492 RA. 2018. NextStrain: Real-time tracking of pathogen evolution. *Bioinformatics* 34:4121–4123.
- 493 26. Letunic I, Bork P. 2016. Interactive tree of life (iTOL) v3: an online tool for the display and
494 annotation of phylogenetic and other trees. *Nucleic Acids Res* 44:W242–W245.
- 495 27. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe RL,
496 Rebelo AR, Florensa AF, Fagelhauer L, Chakraborty T, Neumann B, Werner G, Bender JK, Stingl
497 K, Nguyen M, Coppens J, Xavier BB, Malhotra-Kumar S, Westh H, Pinholt M, Anjum MF, Duggett
498 NA, Kempf I, Nykäsenoja S, Olkkola S, Wiczorek K, Amaro A, Clemente L, Mossong J, Losch S,
499 Ragimbeau C, Lund O, Aarestrup FM. 2020. ResFinder 4.0 for predictions of phenotypes from
500 genotypes. *J Antimicrob Chemother* 75:3491–3500.
- 501 28. RStudio Team (2020). RStudio: Integrated Development for R. RStudio, PBC, Boston, MA URL
502 <http://www.rstudio.com/>.
- 503 29. Li H. 2018. Minimap2: Pairwise alignment for nucleotide sequences. *Bioinformatics* 34:3094–3100.
- 504 30. Xu Y, Lewandowski K, Downs L, Kavanagh J, Hender T, Lumley S, Jeffery K, Foster D, Sanderson
505 N, Vaughan A, Morgan M, Vipond R, Carroll M, Peto T, Crook D, Walker AS, Matthews P, Pullan
506 S. 2021. Nanopore metagenomic sequencing of influenza virus directly from respiratory samples:
507 diagnosis, drug resistance and nosocomial transmission. *Eurosurveillance* 26:1–12.
- 508 31. Xu Y, Lewandowski K, Lumley S, Pullan S, Vipond R, Carroll M, Foster D, Matthews PC, Peto T,
509 Crook D. 2018. Detection of viral pathogens with multiplex nanopore MinION sequencing: Be
510 careful with cross-Talk. *Front Microbiol* 9:1–7.

- 511 32. Wick RR, Judd LM, Holt KE. 2018. Deepbiner: Demultiplexing barcoded Oxford Nanopore reads
512 with deep convolutional neural networks. *PLoS Comput. Biol.* doi.org/10.1371/journal.pcbi.1006583
- 513 33. Klaudia Chrzastek, Chandana Tennakoon, Dagmara Bialy, Graham Freimanis JF and HS. 2021. A
514 random priming amplification method for whole genome sequencing of SARS-CoV-2 and H1N1
515 influenza A virus. *bioRxiv* 2021.06.25.449750.
- 516 34. Kafetzopoulou LE, Efthymiadis K, Lewandowski K, Crook A, Carter D, Osborne J, Aarons E,
517 Hewson R, Hiscox JA, Carroll MW, Vipond R, Pullan ST. 2018. Assessment of metagenomic
518 Nanopore and Illumina sequencing for recovering whole genome sequences of chikungunya and
519 dengue viruses directly from clinical samples. *Eurosurveillance* 23:1–13.
- 520 35. Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F. 2019. SHERLOCK: nucleic acid
521 detection with CRISPR nucleases. *Nat Protoc* 14:2986–3012.
- 522 36. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, Soucy JPR, Daneman
523 N. 2020. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid
524 review and meta-analysis. *Clin Microbiol Infect* 26:1622–1629.
- 525 37. Lansbury L, Lim B, Baskaran V, Lim WS. 2020. Co-infections in people with COVID-19: a
526 systematic review and meta-analysis. *J Infect* 81:266–275.
- 527 38. Karaba SM, Jones G, Hessel T, Smith LL, Avery R, Dzintars K, Salinas AB, Keller SC, Townsend
528 JL, Klein E, Amoah J, Garibaldi BT, Cosgrove SE, Fabre V. 2021. Prevalence of co-infection at the
529 time of hospital admission in COVID-19 Patients, A multicenter study. *Open Forum Infect Dis* 8:1–
530 7.
- 531 39. Quick J, Grubaugh ND, Pullan ST, Claro IM, Smith AD, Gangavarapu K, Oliveira G, Robles-
532 Sikisaka R, Rogers TF, Beutler NA, Burton DR, Lewis-Ximenez LL, Jesus JG de, Giovanetti M,
533 Hill S, Black A, Bedford T, Carroll MW, Nunes M, Jr LCA, Sabino EC, Baylis SA, Faria N, Loose
534 M, Simpson JT, Pybus OG, Andersen KG, Loman NJ. 2017. Zika and other virus genomes directly
535 from clinical samples. *Nat Protoc* 12:1261–1276.

- 536 40. Chorlton SD, Ritchie G, Lawson T, McLachlan E, Romney MG, Matic N, Lowe CF. 2021. Next-
537 generation sequencing for cytomegalovirus antiviral resistance genotyping in a clinical virology
538 laboratory. *Antiviral Res* 192:105123.
- 539 41. Matic N, Lowe CF, Ritchie G, Stefanovic A, Lawson T, Jang W, Young M, Dong W, Brumme ZL,
540 Brumme CJ, Leung V, Romney MG. 2021. Rapid detection of SARS-CoV-2 variants of concern,
541 including B.1.1.28/P.1, British Columbia, Canada. *Emerg Infect Dis* 27:1673–1676.
- 542 42. Kinloch NN, Ritchie G, Brumme CJ, Dong W, Dong W, Lawson T, Brad Jones R, Montaner JSG,
543 Leung V, Romney MG, Stefanovic A, Matic N, Lowe CF, Brumme ZL. 2020. Suboptimal
544 biological sampling as a probable cause of false-negative COVID-19 diagnostic test results. *J Infect*
545 *Dis* 222:899–902.
- 546 43. Deng X, Achari A, Federman S, Yu G, Somasekar S, Bártolo I, Yagi S, Mbala-Kingebeni P,
547 Kapetshi J, Ahuka-Mundeke S, Muyembe-Tamfum JJ, Ahmed AA, Ganesh V, Tamhankar M,
548 Patterson JL, Ndembi N, Mbanya D, Kaptue L, McArthur C, Muñoz-Medina JE, Gonzalez-Bonilla
549 CR, López S, Arias CF, Arevalo S, Miller S, Stone M, Busch M, Hsieh K, Messenger S, Wadford
550 DA, Rodgers M, Cloherty G, Faria NR, Thézé J, Pybus OG, Neto Z, Morais J, Taveira N, R. Hackett
551 J, Chiu CY. 2020. Metagenomic sequencing with spiked primer enrichment for viral diagnostics and
552 genomic surveillance. *Nat Microbiol* 5:443–454.
- 553 44. Yap M, Feehily C, Walsh CJ, Fenelon M, Murphy EF, McAuliffe FM, van Sinderen D, O’Toole
554 PW, O’Sullivan O, Cotter PD. 2020. Evaluation of methods for the reduction of contaminating host
555 reads when performing shotgun metagenomic sequencing of the milk microbiome. *Sci Rep* 10:1–11.
- 556 45. Ji XC, Zhou LF, Li CY, Shi YJ, Wu ML, Zhang Y, Fei XF, Zhao G. 2020. Reduction of Human
557 DNA Contamination in Clinical Cerebrospinal Fluid Specimens Improves the Sensitivity of
558 Metagenomic Next-Generation Sequencing. *J Mol Neurosci* 70:659–666.

559

560

561 **Table 1: Study sample descriptions and sequencing results**

Study ID	Collection Location	Swab Type	Collection Date	Ct Value	Gene	Kit	Reads	Dual Barcode	% Human	RPM (Dual Barcode)
P1	VGH	NPS	Fall 2020	37.1	ORF1ab	SQK-LSK109	2,592,365	580,829	90	3,030.15
P2	VGH	NPS	Fall 2020	24.1	ORF1ab	SQK-LSK109	2,196,488	425,936	50	62,401.39
P3	VGH	NPS	Fall 2020	14.7	ORF1ab	SQK-LSK109	1,480,039	268,331	8	889,826.37
P4	Oxford	OPS	Spring 2020	25.4	E-gene	SQK-LSK109	1,681,970	194,567	62	3,135.17
P5	Oxford	OPS	Spring 2020	29.9	E-gene	SQK-LSK109	1,487,346	369,374	81	2.71
P6	Oxford	OPS	Spring 2020	34.1	E-gene	SQK-LSK109	1,484,871	224,739	39	0
P7	Oxford	OPS	Spring 2020	35.4	E-gene	SQK-LSK109	1,871,165	315,162	88	0
P8	Oxford	OPS	Spring 2020	38.7	E-gene	SQK-LSK109	4,892,596	1,648,997	79	0
P9	Oxford	OPS	Spring 2020	31.7	E-gene	SQK-LSK109	3,095,244	853,190	54	0
P10	Oxford	OPS	Spring 2020	Indeterminate	E-gene	SQK-LSK109	3,195,376	1,209,061	65	0
P11	Oxford	OPS	Spring 2020	Indeterminate	E-gene	SQK-LSK109	2,642,491	758,333	28	0
P12	BCCDC	NPS	Fall 2020	36.13	E-gene	SQK-LSK110	1,894,335	425,729	91	2.35
P13	BCCDC	NPS	Fall 2020	35.21	E-gene	SQK-LSK110	2,612,555	636,570	0.2	0
P14	BCCDC	NPS	Fall 2020	33.33	E-gene	SQK-LSK110	3,335,378	794,876	16	1.26
P15	BCCDC	NPS	Fall 2020	33.73	E-gene	SQK-LSK110	3,689,514	897,886	98	0
P16	BCCDC	NPS	Fall 2020	33.63	E-gene	SQK-LSK110	2,301,355	593,209	80	5.06
P17	BCCDC	NPS	Fall 2020	Indeterminate	NA	SQK-LSK110	1,412,609	384,971	10	38.96
P18	BCCDC	NPS	Fall 2020	Indeterminate	NA	SQK-LSK110	1,269,020	256,134	92	0
P19	BCCDC	NPS	Fall 2020	36.33	E-gene	SQK-LSK110	2,588,988	744,812	82	0
P20	VGH	NPS	Spring 2021	35.6	ORF1ab	SQK-LSK110	1,535,450	431,421	48	2.32
P21	VGH	NPS	Spring 2021	34.3	ORF1ab	SQK-LSK110	1,553,510	411,279	37	2.43
P22	VGH	NPS	Spring 2021	33.7	ORF1ab	SQK-LSK110	1,206,439	328,369	47	3.05
P23	VGH	NPS	Spring 2021	21.4	ORF1ab	SQK-LSK110	1,584,504	499,025	7	17,462.05
P24	VGH	NPS	May 2021	15.5	ORF1ab	SQK-LSK110	2,875,078	728,905	84	58,192.77
P25	VGH	NPS	May 2021	16.1	ORF1ab	SQK-LSK110	2,184,440	484,358	87	68,748.74
P26	VGH	NPS	May 2021	16.1	ORF1ab	SQK-LSK110	968,712	301,091	49	493,422.25
P27	VGH	NPS	May 2021	17	ORF1ab	SQK-LSK110	2,550,631	737,603	81	60,411.90
P28	VGH	NPS	May 2021	17.7	ORF1ab	SQK-LSK110	2,151,872	503,298	87	22,088.31
P29	VGH	NPS	May 2021	20	ORF1ab	SQK-LSK110	993,047	212,823	77	47,057.88
P30	VGH	NPS	Dec 2020	22	E-gene	SQK-LSK110	707,288	253,025	81	171,129.34
P31	VGH	NPS	May 2021	22.8	ORF1ab	SQK-LSK110	2,009,926	456,803	98	1,136.16
P32	VGH	NPS	May 2021	23.5	ORF1ab	SQK-LSK110	3,173,498	687,623	99	373.75
P33	VGH	NPS	May 2021	24.4	ORF1ab	SQK-LSK110	1,597,376	239,837	85	1,054.88
P34	VGH	NPS	May 2021	25.5	ORF1ab	SQK-LSK110	1,103,117	283,010	99	38.87
P35	VGH	NPS	May 2021	27.3	ORF1ab	SQK-LSK110	3,325,162	1,042,089	95	2.88
P36	VGH	NPS	May 2021	27.7	ORF1ab	SQK-LSK110	1,374,869	322,646	87	27.89
P37	VGH	NPS	July 2020	28	E-gene	SQK-LSK110	1,365,733	278,532	86	240.55
P38	VGH	NPS	May 2021	30.6	ORF1ab	SQK-LSK110	4,458,073	1,335,187	98	49.43
N1	VGH	NPS	May 2021	NA	NA	SQK-LSK110	1,803,891	521,584	96	0
N2	VGH	NPS	May 2021	NA	NA	SQK-LSK110	1,932,656	645,041	96	0
N3	VGH	NPS	May 2021	NA	NA	SQK-LSK110	3,421,518	1,053,199	98	0
N4	VGH	NPS	May 2021	NA	NA	SQK-LSK110	4,947,322	1,539,940	75	0
N5	VGH	NPS	May 2021	NA	NA	SQK-LSK110	1,386,059	722,140	90	0

562 **Table 2:** Overall sample classification, before adjustment for barcode crosstalk

		Positive by mNGS	Negative by mNGS	Sum
True positive	Ct≤30	21	0	21
	Ct>30	8	8	16
True negative		0	5	5
Sum		29	13	

563

564 **Table 3:** Overall sample classification, after adjustment for barcode crosstalk

		Positive by mNGS	Negative by mNGS	Sum
True positive	Ct≤30	20	1	21
	Ct>30	2	14	16
True negative		0	5	5
Sum		22	20	

565

566

567

568

569

570

571

572

573

574

575 **Table 4:** Percent SARS-CoV-2 genome coverage for samples classified as mNGS SARS-CoV-2 positive
576 following 0.2% crosstalk correction

Study ID	Ct Value	RPM (Dual Barcode)	50X Coverage	20X Coverage	1X Coverage
P1	37.1	3,030.15	26.25	80.09	99.85
P2	24.1	62,401.39	99.85	99.94	100
P3	14.7	889,826.37	99.98	100	100
P4	25.4	3,135.17	1.57	23.71	100
P23	21.4	17,462.05	98.85	99.78	99.95
P24	15.5	58,192.77	99.8	99.91	100
P25	16.1	68,748.74	99.85	99.97	100
P26	16.1	493,422.25	99.99	100	100
P27	17	60,411.90	99.81	99.89	100
P28	17.7	22,088.31	99.78	99.79	100
P29	20	47,057.88	99.59	99.75	100
P30	22	171,129.34	99.8	99.85	100
P31	22.8	1,136.16	0	20.01	99.99
P32	23.5	373.75	0	3.87	98.94
P33	24.4	1,054.88	0	0	98.74
P34	25.5	38.87	0	0	15.25
P35	27.3	2.88	0	0	3.63
P36	27.7	27.89	0	0.3	3.85
P37	28	240.55	0	0.07	47.25
P38	30.6	49.43	0	0	72.79

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591


592 **Table 5: SARS-CoV-2 Variant of Concern PCR and Pangolin classification results**

Study ID	RPM (Dual Barcode)	VOC PCR Result	Pangolin Lineage (Scorpio Call)
P1	3,030.15	Not Performed	B.1.2
P2	62,401.39	Not Performed	B.1.128
P3	889,826.37	Not Performed	B.1.2
P4	3,135.17	Not Performed	None
P23	17,462.05	Not Performed	B.1.2
P24	58,192.77	Not Performed	P.1 (Gamma)
P25	68,748.74	Presumptive Positive Variant of Concern. Spike gene N501Y and E484K mutations DETECTED by NAT.	P.1 (Gamma)
P26	493,422.25	Presumptive Positive B.1.1.7 Variant of Concern. Spike gene N501Y mutation DETECTED by NAT. No E484K mutation detected.	B.1.1.7 (Alpha)
P27	60,411.90	Presumptive Positive B.1.1.7 Variant of Concern. Spike gene N501Y mutation DETECTED by NAT. No E484K mutation detected.	B.1.1.7 (Alpha)
P28	22,088.31	Presumptive Positive Variant of Concern. Spike gene N501Y and E484K mutations DETECTED by NAT.	P.1 (Gamma)
P29	47,057.88	Presumptive Positive B.1.1.7 Variant of Concern. Spike gene N501Y mutation DETECTED by NAT. No E484K mutation detected.	B.1.1.7 (Alpha)
P30	171,129.34	Not Performed	B.1.36.36
P31	1,136.16	Presumptive Positive Variant of Concern. Spike gene N501Y and E484K mutations DETECTED by NAT.	None
P32	373.75	Negative. No Spike gene N501Y or E484K mutations detected by NAT.	None
P33	1,054.88	Presumptive Positive B.1.1.7 Variant of Concern. Spike gene N501Y mutation DETECTED by NAT. No E484K mutation detected.	None
P34	38.87	Presumptive Positive Variant of Concern. Spike gene N501Y and E484K mutations DETECTED by NAT.	None
P35	2.88	Not Performed	None
P36	27.89	Presumptive Positive Variant of Concern. Spike gene N501Y and E484K mutations DETECTED by NAT.	None
P37	240.55	Not Performed	None
P38	49.43	Negative. No Spike gene N501Y or E484K mutations detected by NAT.	None

593

594

595



596

597 **Figure 1:** Log SARS-CoV-2 reads per million reads sequenced across C_t value (E gene or ORF1ab) for
598 all RT-qPCR positive samples. 95% confidence intervals for the linear regression line are shaded in grey.

599 Coefficient of determination = 0.71.

600


601

602



603
604 **Figure 2:** Coverage depth for samples classified as positive by our classifier with log depth of coverage
605 on the y-axis and SARS-CoV-2 reference genome position on the x-axis

606
607
608
609
610
611
612
613
614



615


616 **Figure 3:** Probability of obtaining greater than 95% genome coverage (1 = Yes, 0 = No) for RT-qPCR
617 positive study samples across C_t value for **a.** 1x, **b.** 20x, and **c.** 50x genome coverage. Logistic regression
618 models are represented in blue.

619

620

621

622



623
624 **Figure 4:** Study samples (marked as P1, P2, etc.) and their nearest three neighbors from all publicly
625 available SARS-CoV-2 sequences
626
627
628
629
630
631
632
633
634
635